Overview

A Study of Cetrelimab in Participants With Chronic Hepatitis B Virus Infection

Status:
Not yet recruiting
Trial end date:
2024-04-15
Target enrollment:
Participant gender:
Summary
The purpose of the study is to characterize the pharmacokinetic (PK) profile of cetrelimab administered intravenous (IV) or subcutaneous (SC) in chronic hepatitis B (CHB) participants.
Phase:
Phase 1
Details
Lead Sponsor:
Janssen Research & Development, LLC